BRCA2 and breast cancer: There is evidence that BRCA1/2-mutated tumors exhibit significantly increased CD8+ TILs (22), although in breast cancer, differential modulation between BRCA1 and BRCA2 mutations in the tumor immune microenvironment has been found (72).